Siegel F, Siegel S, Kotýnková K, et al. Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer. Cancer discovery. 2025. doi:10.1158/2159-8290.CD-25-0605
Cancer Program
Shanmugam V, Tokcan N, Chafamo D, et al. Genome-scale spatial mapping of the Hodgkin lymphoma microenvironment identifies tumor cell survival factors. Nature communications. 2025. doi:10.1038/s41467-025-67539-1
Vinyard ME, Rasmussen AW, Li R, Klein AM, Getz G. Learning cell dynamics with neural differential equations. Nature Machine Intelligence. 2025;7. doi:10.1038/s42256-025-01150-3
Sadagopan A, Carson M, Zamurs EJ, et al. Mutant p53 protein accumulation is selectively targetable by proximity-inducing drugs. Nature chemical biology. 2025. doi:10.1038/s41589-025-02051-7
Chen XD, Chen Z, Wythes G, et al. Helicase-assisted continuous editing for programmable mutagenesis of endogenous genomes. Science (New York, N.Y.). 2024;386(6718):eadn5876. doi:10.1126/science.adn5876
Loi S, Settleman J, Joyce JA, et al. The next big questions in cancer research. Cell. 2023;186(8):1523-1527. doi:10.1016/j.cell.2023.01.037
Sun Y, Revach OY, Anderson S, et al. Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature. 2023. doi:10.1038/s41586-023-05704-6
Dubrot J, Du PP, Lane-Reticker SK, et al. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nat Immunol. 2022;23(10):1495-1506. doi:10.1038/s41590-022-01315-x
Bondeson DP, Paolella BR, Asfaw A, et al. Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer. Nat Cancer. 2022. doi:10.1038/s43018-022-00360-7
Lin S, Larrue C, Scheidegger NK, et al. An In Vivo CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML. Cancer Discov. 2022;12(2):432-449. doi:10.1158/2159-8290.CD-20-1851